A detailed history of United Capital Financial Advisers, LLC transactions in Biomarin Pharmaceutical Inc stock. As of the latest transaction made, United Capital Financial Advisers, LLC holds 4,742 shares of BMRN stock, worth $329,616. This represents 0.0% of its overall portfolio holdings.

Number of Shares
4,742
Previous 6,150 22.89%
Holding current value
$329,616
Previous $537,000 27.37%
% of portfolio
0.0%
Previous 0.0%

Shares

20 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 14, 2024

SELL
$74.43 - $92.22 $104,797 - $129,845
-1,408 Reduced 22.89%
4,742 $390,000
Q1 2024

May 15, 2024

BUY
$83.81 - $99.0 $272,382 - $321,750
3,250 Added 112.07%
6,150 $537,000
Q4 2023

Feb 14, 2024

BUY
$76.22 - $98.51 $16,463 - $21,278
216 Added 8.05%
2,900 $279,000
Q3 2023

Nov 14, 2023

BUY
$85.07 - $94.48 $2,381 - $2,645
28 Added 1.05%
2,684 $237,000
Q2 2023

Aug 14, 2023

SELL
$86.68 - $100.3 $26,264 - $30,390
-303 Reduced 10.24%
2,656 $230,000
Q1 2023

Aug 14, 2023

BUY
$87.74 - $117.27 $26,585 - $35,532
303 Added 11.41%
2,959 $287,000
Q1 2023

May 15, 2023

SELL
$87.74 - $117.27 $177,761 - $237,589
-2,026 Reduced 40.64%
2,959 $287,000
Q4 2022

Feb 14, 2023

SELL
$80.93 - $108.63 $745,203 - $1 Million
-9,208 Reduced 64.88%
4,985 $515,000
Q3 2022

Nov 14, 2022

SELL
$82.16 - $96.94 $3,450 - $4,071
-42 Reduced 0.3%
14,193 $1.2 Million
Q2 2022

Aug 11, 2022

SELL
$71.48 - $86.85 $26,805 - $32,568
-375 Reduced 2.57%
14,235 $1.18 Million
Q1 2022

May 16, 2022

SELL
$74.28 - $92.69 $17,827 - $22,245
-240 Reduced 1.62%
14,610 $1.13 Million
Q4 2021

Feb 14, 2022

SELL
$71.72 - $91.47 $30,122 - $38,417
-420 Reduced 2.75%
14,850 $1.31 Million
Q3 2021

Nov 15, 2021

BUY
$74.77 - $85.47 $7,103 - $8,119
95 Added 0.63%
15,270 $1.18 Million
Q2 2021

Aug 13, 2021

SELL
$75.51 - $84.79 $640,551 - $719,273
-8,483 Reduced 35.86%
15,175 $1.27 Million
Q1 2021

May 14, 2021

BUY
$74.73 - $90.69 $1.08 Million - $1.31 Million
14,391 Added 155.29%
23,658 $1.79 Million
Q4 2020

Feb 17, 2021

SELL
$72.61 - $90.2 $646,156 - $802,689
-8,899 Reduced 48.99%
9,267 $813,000
Q3 2020

Nov 13, 2020

BUY
$71.87 - $131.03 $915,120 - $1.67 Million
12,733 Added 234.36%
18,166 $1.38 Million
Q2 2020

Aug 13, 2020

BUY
$79.55 - $124.22 $19,092 - $29,812
240 Added 4.62%
5,433 $670,000
Q1 2020

May 15, 2020

BUY
$71.37 - $96.85 $103,272 - $140,141
1,447 Added 38.63%
5,193 $439,000
Q4 2019

Feb 14, 2020

BUY
$64.27 - $86.37 $240,755 - $323,542
3,746 New
3,746 $317,000

Others Institutions Holding BMRN

About BIOMARIN PHARMACEUTICAL INC


  • Ticker BMRN
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 185,824,000
  • Market Cap $12.9B
  • Description
  • BioMarin Pharmaceutical Inc. develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Its commercial products include Vimizim, an enzyme replacement therapy for the treatment of mucopolysaccharidosis (MPS) IV type A, a lysosomal storage disorder; Naglazyme, a recombinant form of N-a...
More about BMRN
Track This Portfolio

Track United Capital Financial Advisers, LLC Portfolio

Follow United Capital Financial Advisers, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of United Capital Financial Advisers, LLC, based on Form 13F filings with the SEC.

News

Stay updated on United Capital Financial Advisers, LLC with notifications on news.